Skip to main content

Table 3 Summary of the immunohistochemistry analyses of the xenografts obtained with cancer patients’ serum-treated BRCA1-KO fibroblasts

From: Transfer of malignant trait to BRCA1 deficient human fibroblasts following exposure to serum of cancer patients

Cases Xenograft Phenotype Differentiation Markers
Case A Poorly differentiated carcinoma Synaptophysin
Neurofilament
negative
negative
Case B Poorly differentiated carcinoma Estrogen receptor
Mammoglobin
CK7
negative
rare positivity
rare positivity
Case C Poorly differentiated carcinoma Chromogranin
Synaptophysin
negative
rare positivity
rare positivity
Case D Poorly differentiated carcinoma Estrogen receptor
Mammoglobin
CK7
negative
negative
rare positivity
Case F Poorly differentiated carcinoma CK5/6
CK34BE12
AE1/AE3
negative
negative
Strongly + ve
Case E Differentiation toward intestinal adenocarcinoma CEA
CK7
CK20
CDX-2
AE1/AE3
Vimentin
positive
negative
positive
positive
positive
negative
Case G Differentiation toward intestinal adenocarcinoma CEA
CK7
CK20
CDX-2
AE1/AE3
Vimentin
positive
negative
positive
positive
positive
negative
Case H Differentiation toward intestinal adenocarcinoma CEA
CK7
CK20
CDX-2
AE1/AE3
Vimentin
positive
negative
positive
positive
positive
negative
Case I Differentiation toward intestinal adenocarcinoma CEA
CK7
CK20
CDX-2
AE1/AE3
Vimentin
positive
negative
positive
positive
positive
negative
Case J Differentiation toward typical pancreatic ductal adenocarcinoma CK7
CK19
AE1/AE3
Vimentin
positive
positive
positive
negative